DaVita: Treatment Volume Recovery Meets the Reimbursement Pressure Nobody Wants to Talk About

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

DaVita reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to actual earnings.

Historical price action around DaVita earnings shows extreme volatility, with an average absolute Day +1 move of 12.41%—significantly higher than typical healthcare stocks. The most recent Q2 2026 report exemplifies this pattern: despite beating estimates, the stock plunged -17.24% the following day, the largest decline in the dataset. This suggests investors are focused less on the headline beat and more on guidance, margins, or forward commentary.

The direction of moves has been predominantly negative in recent reports, with five of the last eight earnings triggering Day +1 declines. Even quarters with strong fundamental beats (Q1 2026's +19.09% EPS surprise) have produced mixed results—that report generated a +23.46% gain, but it remains the exception rather than the rule. The Day 0 moves average just 1.67%, indicating limited anticipatory positioning, while the Day +1 range of 9.42% confirms that the real action happens after investors digest the full results and guidance.

Part 2.2: Options Market Expected Move

The options market is pricing in a 9.71% expected move for this earnings release, which sits below the 12.41% average absolute Day +1 move from recent history. This suggests options traders may be underpricing the potential volatility, particularly given DaVita's track record of double-digit post-earnings swings and the -17.24% decline following last quarter's report.

Part 3: What Analysts Are Saying

Analyst sentiment on DaVita remains cautiously mixed, with a consensus rating of 3.63 (between Hold and Buy) and an average price target of $223.43—implying 21.5% upside from the current price of $183.93. The analyst community is split: 3 Strong Buys and 4 Holds are offset by 1 Moderate Sell, reflecting divergent views on the company's ability to sustain recent operational improvements.

The rating breakdown has remained unchanged over the past month, with no upgrades or downgrades, suggesting analysts are in wait-and-see mode ahead of this report. Price targets span a wide range from a low of $180.00 to a high of $270.00, underscoring the uncertainty around DaVita's valuation and future trajectory.

The lack of recent estimate revisions—analysts have "generally reconfirmed their estimates over the last 30 days"—indicates stable expectations but also suggests limited conviction. Given the stock's significant underperformance following last quarter's beat, analysts appear to be withholding judgment until management can demonstrate more consistent execution and provide credible forward guidance that restores investor confidence.

Part 4: Technical Picture

DaVita's technical setup heading into earnings shows modest improvement but remains fragile. The Barchart Technical Opinion currently registers a 16% Buy signal, a notable improvement from the 32% Sell signal just one week ago and the 24% Sell reading a month ago. This recent shift suggests short-term momentum has turned positive, though the low absolute percentage indicates the conviction behind the move remains weak.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has turned positive but lacks strong conviction
• Medium-term (Hold): Neutral reading suggests the intermediate trend remains in consolidation mode
• Long-term (Hold): Neutral signal reflects an absence of clear directional bias in the longer-term trend

Trend Characteristics: The technical environment shows Minimum strength with the Weakest direction, indicating the recent improvement is tentative and vulnerable to reversal on disappointing results.

The stock is currently trading at $183.93, positioned above its 5-day ($183.88), 10-day ($183.50), 20-day ($181.34), 50-day ($180.83), and 200-day ($176.15) moving averages, but remains below the 100-day average at $198.24. This configuration suggests the stock has stabilized after earlier weakness and is attempting to build a base, but the failure to reclaim the 100-day average indicates overhead resistance remains significant.

Key resistance sits at the 100-day moving average of $198.24, which has capped recent rallies and represents a critical level for bulls to reclaim. Support appears solid near the 50-day average at $180.83, which has provided a floor over the past month. The overall technical setup is cautiously supportive—the stock has stabilized and short-term momentum has improved—but the weak trend characteristics and proximity to support levels suggest limited cushion if earnings disappoint. Given the options market's 9.71% expected move and DaVita's history of violent post-earnings reactions, traders should be prepared for a decisive break in either direction.